Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present PDL BioPharma, Inc. (NASDAQ: PDLI).

Full DD Report for PDLI

You must become a subscriber to view this report.


Recent News from (NASDAQ: PDLI)

3 Health Care Stocks Rallying After US Midterms
CORAL GABLES, FL / ACCESSWIRE / November 7, 2018 / Healthcare stocks are rallying after Tuesday's US midterm elections . The Sector SPD Healthcare ETF (XLV) has climbed to highs of $92.24 as of 9:45AM EST. According to Modern Healthcare* the healthcare industry will continue to drive t...
Source: ACCESSWIRE IA
Date: November, 07 2018 17:45
PDL BioPharma Inc. (PDLI) CEO John McLaughlin on Q3 2018 Results - Earnings Call Transcript
PDL BioPharma, Inc. (PDLI) Q3 2018 Results Earnings Conference Call November 06, 2018, 04:30 PM ET Executives Jody Cain - Investor Relations John McLaughlin - Chief Executive Officer Dominique Monnet - President Peter Garcia - Chief Financial Officer Analysts Phil Nadeau ...
Source: SeekingAlpha
Date: November, 06 2018 20:23
PDL BioPharma, Inc. 2018 Q3 - Results - Earnings Call Slides
The following slide deck was published by PDL BioPharma, Inc. in conjunction with their 2018 Q3 earnings Read more ...
Source: SeekingAlpha
Date: November, 06 2018 19:25
PDL BioPharma beats by $0.02, beats on revenue
PDL BioPharma (NASDAQ: PDLI ): Q3 Non-GAAP EPS of $0.09 beats by $0.02 ; GAAP EPS of $0.18 beats by $0.11 . Revenue of $67.9M (+8.2% Y/Y) beats by $17.3M . Shares +7.7% . Press Release More news on: PDL BioPharma, Inc., Earnings news and commentary, Stocks on the move, Healthca...
Source: SeekingAlpha
Date: November, 06 2018 16:30
PDL BioPharma Reports Third Quarter 2018 Financial Results
INCLINE VILLAGE, Nev. , Nov. 6, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) reports financial results for the three and nine months ended September 30, 2018 including: Third Quarter Financial Highlights Total revenues of $67.9 million ....
Source: PR Newswire
Date: November, 06 2018 16:05
PDL BioPharma to Announce Third Quarter Financial Results on November 6, 2018
INCLINE VILLAGE, Nev. , Oct. 31, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today announced that it will release its third quarter financial results for the period ended September 30, 2018 , on Tuesday, November 6, 2018 , after market close.&#x...
Source: PR Newswire
Date: October, 31 2018 16:05
SevenSaoi Capital Delivers Letter to the Board of PDL BioPharma
CHICAGO , Sept. 20, 2018 /PRNewswire/ -- SevenSaoi Capital, LLC (together with its affiliates, "SevenSaoi," pronounced "7C"), a long-only public equity investment firm and significant shareholder in PDL BioPharma, Inc. (NasdaqGS: PDLI) ("PDL" or the "Company") with 2,590,198 shares of com...
Source: PR Newswire
Date: September, 20 2018 08:30
PDL BioPharma (PDLI) Presents At Rodman & Renshaw.C. Wainwright 20th Annual Global Investment Conference - Slideshow
The following slide deck was published by PDL BioPharma, Inc. in conjunction with this Read more ...
Source: SeekingAlpha
Date: September, 07 2018 13:32
PDL BioPharma to Present at the H.C. Wainwright 20th Annual Global Investment Conference
INCLINE VILLAGE, Nev. , Aug. 30, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that John McLaughlin , PDL's chief executive officer, will present at the H.C. Wainwright 20 th Annual Global Investment Conference next week in New York City...
Source: PR Newswire
Date: August, 30 2018 08:00
Report: Developing Opportunities within Parker Drilling, CoreLogic, Steven Madden, Diebold Nixdorf, Nevro, and PDL BioPharma - Future Expectations, Projections Moving into 2018
NEW YORK, Aug. 28, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Parker Drilling Company (NYSE:PKD), CoreLogic, Inc. (NYSE:CLGX), Steven M...
Source: GlobeNewswire
Date: August, 28 2018 08:20

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-142.932.922.9952.91742,726
2018-12-133.012.973.042.935863,593
2018-12-123.013.0153.042.951,662,567
2018-12-113.033.003.062.935789,581
2018-12-102.993.013.0352.935973,250

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-14219,065363,52560.2613Short
2018-12-13203,649314,19564.8161Short
2018-12-12209,191700,17729.8769Cover
2018-12-11168,625372,14745.3114Short
2018-12-10115,495432,65926.6942Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on PDLI.


About PDL BioPharma, Inc. (NASDAQ: PDLI)

Logo for PDL BioPharma, Inc. (NASDAQ: PDLI)

Not available

 

Contact Information

 

 

Current Management

  • Mark McDade / CEO
  • Glen Sato / CFO

Current Share Structure

  • Market Cap: $426,059,949 - 05/18/2018
  • Issue and Outstanding: 153,812,256 - 03/13/2018

 


Recent Filings from (NASDAQ: PDLI)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: September, 05 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 12 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 08 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: June, 08 2018

 

 


Daily Technical Chart for (NASDAQ: PDLI)

Daily Technical Chart for (NASDAQ: PDLI)


Stay tuned for daily updates and more on (NASDAQ: PDLI)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: PDLI)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in PDLI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of PDLI and does not buy, sell, or trade any shares of PDLI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/